Results 101 to 110 of about 2,524 (195)

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab

Pediatric Infectious Disease Journal
Background: Nirsevimab is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Although nucleic acid detection by polymerase chain reaction is primarily utilized for the clinical diagnosis of RSV, antigen detection is still routinely used and ...
Sarah R. Sincero, Kelly Ann Mahool, Emma Schaefer, Carolina S. Caceres, Elizabeth J. Kelly, Deidre Wilkins, Kevin M. Tuffy   +6 more
openaire   +2 more sources

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Pelletier, Jonathan H., Rush, Sarah Z., Robinette, Eric, Maholtz, Danielle E., Bigham, Michael T., Forbes, Michael L., Shein, Steven L., Karsies, Todd J., Horvat, Christopher M.   +8 more
openaire   +2 more sources

First- and Second-Year Outcomes After Nirsevimab Immunization

JAMA Pediatrics
Importance The consistency of nirsevimab effectiveness across consecutive seasons and its broader clinical protective effects remain to be fully characterized. Objective To assess whether first-season effectiveness of nirsevimab ...
Gabet, Amélie, Kolla, Epiphane, Tréluyer, Ludovic, Bertrand, Marion, Jabagi, Marie-Joelle, Weill, Olivia, Rachas, Antoine, Olié, Valérie, Zureik, Mahmoud   +8 more
openaire   +2 more sources

Guideline for Weighing of Infants for Nirsevimab Administration.

Purpose To provide a standardised approach to determine the correct Nirsevimab dose for infants attending a catch-up clinic including mobile vaccination clinics: ensuring accurate dosing while avoiding unnecessary ...
Health Protection Surveillance Centre (HPSC)
core  

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

The study was funded by the Institute of Health Carlos III (on its own budget) which, at the institutional level, had no role in the study design, data collection, analysis or interpretation.Using real-life data from Spain between October 2023 and March ...
Nuñez, Olivier, Pastor-Barriuso, Roberto, Monge Corella, Susana, Nirsevimab Effectiveness Study Collaborators, Jarrin Vera, Inmaculada   +4 more
core   +1 more source

Nirsevimab som skydd mot Respiratorisk syncytialvirus (RSV) hos spädbarn : Hur effektivt och säkert är nirsevimab som skydd mot RSV hos friska spädbarn?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among children and represents a major global health concern. Most RSV cases occur during the RSV season, which is during the cold seasons of the year. The infection often begins as
Awad, Zainab
core   +1 more source

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration

Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants and older adults. In Spain, surveillance is supported by the SiVIRA system and the RELECOV genomic sequencing network.
Mas, Vicente, Campoy, Albert, García, María Luz, Alcolea, Sonia, Moreno-Parrado, Laura, Reina, Jordi, Calvo, Cristina, Lepe Jiménez, José Antonio, Iglesias-Caballero, María, Casas, Inmaculada, Pérez, Zulema, Lepe, José Antonio, Casas Flecha, Inmaculada, Antón, Andrés, Perez-Castro, Sonia, Navascués, Ana, Camarero-Serrano, Sara, Costa, José, Cano, Olga, Pozo Sanchez, Francisco, Fernández-González, Ana, Davina-Nunez, Carlos, Gaona, Cristina, Vázquez-Morón, Sonia, Mas-Lloret, Vicente, García-Martínez de Artola, Diego   +25 more
core   +1 more source

Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025. [PDF]

Hosp Pediatr
Teoh Z, Tannis A, Sullivan E, Boom JA, Halasa N, Michaels MG, Payne DC, Sahni LC, Schuster J, Selvarangan R, Staat MA, Stewart LS, Szilagyi PG, Weinberg GA, Williams JV, Dawood FS, Klein EJ, Moline H, Englund JA, Zerr DM.   +19 more
europepmc   +1 more source